| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peptides | 46 | 2025 | 574 | 7.670 |
Why?
|
| Antigen Presentation | 29 | 2025 | 237 | 6.440 |
Why?
|
| Histocompatibility Antigens Class II | 21 | 2025 | 182 | 5.270 |
Why?
|
| HLA-D Antigens | 12 | 2018 | 19 | 4.400 |
Why?
|
| CD4-Positive T-Lymphocytes | 28 | 2023 | 641 | 4.190 |
Why?
|
| Epitopes, T-Lymphocyte | 18 | 2023 | 181 | 4.080 |
Why?
|
| HLA-DR1 Antigen | 23 | 2018 | 27 | 3.540 |
Why?
|
| Aminopeptidases | 9 | 2022 | 27 | 3.470 |
Why?
|
| Herpesvirus 6, Human | 7 | 2024 | 17 | 3.140 |
Why?
|
| Antigens | 8 | 2024 | 147 | 2.570 |
Why?
|
| T-Lymphocytes | 15 | 2025 | 1007 | 2.470 |
Why?
|
| Receptors, Antigen, T-Cell | 14 | 2023 | 287 | 2.440 |
Why?
|
| Lymphocyte Activation | 16 | 2025 | 760 | 2.170 |
Why?
|
| Roseolovirus Infections | 5 | 2022 | 10 | 2.090 |
Why?
|
| Protein Binding | 32 | 2024 | 1602 | 2.080 |
Why?
|
| Peptide Fragments | 11 | 2019 | 410 | 2.000 |
Why?
|
| Epitopes | 15 | 2025 | 289 | 1.960 |
Why?
|
| Vaccinia virus | 7 | 2013 | 71 | 1.800 |
Why?
|
| Minor Histocompatibility Antigens | 8 | 2022 | 35 | 1.720 |
Why?
|
| Amino Acid Sequence | 34 | 2021 | 1592 | 1.670 |
Why?
|
| Viral Proteins | 10 | 2024 | 262 | 1.330 |
Why?
|
| Antigen-Presenting Cells | 7 | 2021 | 178 | 1.310 |
Why?
|
| Models, Molecular | 20 | 2018 | 1148 | 1.280 |
Why?
|
| CD8-Positive T-Lymphocytes | 8 | 2021 | 674 | 1.280 |
Why?
|
| HLA-DR Antigens | 6 | 2021 | 26 | 1.230 |
Why?
|
| Crystallography, X-Ray | 15 | 2024 | 433 | 1.180 |
Why?
|
| Immunodominant Epitopes | 5 | 2019 | 56 | 1.100 |
Why?
|
| Complementarity Determining Regions | 5 | 2019 | 38 | 1.070 |
Why?
|
| Humans | 83 | 2025 | 63292 | 1.030 |
Why?
|
| Epitope Mapping | 6 | 2021 | 50 | 1.020 |
Why?
|
| Molecular Sequence Data | 23 | 2016 | 1990 | 0.990 |
Why?
|
| HLA-A2 Antigen | 6 | 2020 | 64 | 0.970 |
Why?
|
| GPI-Linked Proteins | 3 | 2024 | 40 | 0.950 |
Why?
|
| Endoplasmic Reticulum | 7 | 2022 | 173 | 0.920 |
Why?
|
| Animals | 48 | 2025 | 20631 | 0.920 |
Why?
|
| Lymph | 5 | 2024 | 10 | 0.910 |
Why?
|
| Polymorphism, Genetic | 2 | 2021 | 191 | 0.900 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2024 | 5 | 0.890 |
Why?
|
| Coronavirus OC43, Human | 1 | 2023 | 3 | 0.840 |
Why?
|
| Binding Sites | 12 | 2018 | 903 | 0.840 |
Why?
|
| Islets of Langerhans | 1 | 2025 | 279 | 0.840 |
Why?
|
| Smallpox Vaccine | 4 | 2013 | 14 | 0.830 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2019 | 144 | 0.830 |
Why?
|
| Antigens, Viral | 6 | 2019 | 135 | 0.810 |
Why?
|
| Killer Cells, Natural | 1 | 2024 | 217 | 0.800 |
Why?
|
| Sulfonamides | 2 | 2024 | 127 | 0.800 |
Why?
|
| Protein Conformation | 13 | 2025 | 778 | 0.790 |
Why?
|
| Cytokines | 4 | 2025 | 934 | 0.780 |
Why?
|
| Benzoic Acid | 1 | 2022 | 2 | 0.780 |
Why?
|
| Autoantigens | 4 | 2025 | 138 | 0.780 |
Why?
|
| Immune Tolerance | 4 | 2018 | 176 | 0.770 |
Why?
|
| Herpesvirus 7, Human | 1 | 2022 | 2 | 0.770 |
Why?
|
| Protease Inhibitors | 2 | 2019 | 102 | 0.760 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 8 | 2019 | 119 | 0.760 |
Why?
|
| Lymphocytic choriomeningitis virus | 2 | 2013 | 89 | 0.740 |
Why?
|
| Thymus Gland | 3 | 2021 | 233 | 0.720 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2021 | 120 | 0.720 |
Why?
|
| Cell Line | 14 | 2021 | 2037 | 0.690 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 2019 | 71 | 0.670 |
Why?
|
| Mice, Inbred C57BL | 13 | 2025 | 3391 | 0.660 |
Why?
|
| Mice | 28 | 2025 | 10827 | 0.650 |
Why?
|
| Tryptamines | 1 | 2019 | 13 | 0.650 |
Why?
|
| Gene Products, nef | 3 | 2010 | 13 | 0.650 |
Why?
|
| Protozoan Proteins | 2 | 2014 | 126 | 0.650 |
Why?
|
| Phenylurea Compounds | 1 | 2019 | 32 | 0.650 |
Why?
|
| Cross Reactions | 5 | 2013 | 130 | 0.640 |
Why?
|
| Endosomes | 3 | 2021 | 178 | 0.630 |
Why?
|
| Listeria | 1 | 2019 | 11 | 0.630 |
Why?
|
| Listeriosis | 1 | 2019 | 30 | 0.630 |
Why?
|
| Simian Immunodeficiency Virus | 3 | 2013 | 79 | 0.630 |
Why?
|
| beta 2-Microglobulin | 1 | 2019 | 49 | 0.620 |
Why?
|
| Dendritic Cells | 7 | 2024 | 524 | 0.600 |
Why?
|
| Germ Cells | 1 | 2019 | 110 | 0.590 |
Why?
|
| Autoimmunity | 4 | 2022 | 238 | 0.580 |
Why?
|
| Histocompatibility Antigens | 3 | 2014 | 106 | 0.570 |
Why?
|
| Proteolysis | 1 | 2019 | 145 | 0.570 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2018 | 11 | 0.570 |
Why?
|
| HLA-DR4 Antigen | 3 | 2014 | 9 | 0.570 |
Why?
|
| Hydrogen Bonding | 8 | 2014 | 129 | 0.570 |
Why?
|
| Immunologic Memory | 4 | 2023 | 288 | 0.570 |
Why?
|
| Cell Size | 1 | 2018 | 41 | 0.560 |
Why?
|
| Endocytosis | 2 | 2016 | 152 | 0.560 |
Why?
|
| Membrane Lipids | 1 | 2017 | 27 | 0.560 |
Why?
|
| Viral Load | 2 | 2018 | 231 | 0.550 |
Why?
|
| Fluorescence Polarization | 2 | 2014 | 32 | 0.550 |
Why?
|
| HLA Antigens | 4 | 2022 | 63 | 0.540 |
Why?
|
| Kinetics | 9 | 2018 | 760 | 0.530 |
Why?
|
| Binding, Competitive | 2 | 2014 | 99 | 0.530 |
Why?
|
| Protein Interaction Domains and Motifs | 3 | 2021 | 86 | 0.530 |
Why?
|
| Inflammation | 2 | 2024 | 1146 | 0.510 |
Why?
|
| Cytoplasm | 3 | 2008 | 276 | 0.500 |
Why?
|
| Amino Acid Motifs | 4 | 2021 | 153 | 0.490 |
Why?
|
| Recombinant Proteins | 8 | 2021 | 701 | 0.480 |
Why?
|
| Models, Chemical | 2 | 2015 | 136 | 0.470 |
Why?
|
| Protein Structure, Tertiary | 8 | 2019 | 671 | 0.450 |
Why?
|
| Catalytic Domain | 5 | 2024 | 199 | 0.440 |
Why?
|
| Antibodies, Protozoan | 1 | 2014 | 52 | 0.440 |
Why?
|
| Proteomics | 5 | 2018 | 284 | 0.430 |
Why?
|
| Immunity, Heterologous | 1 | 2013 | 11 | 0.420 |
Why?
|
| Plasmodium falciparum | 2 | 2014 | 246 | 0.420 |
Why?
|
| Protein Structure, Secondary | 8 | 2017 | 260 | 0.420 |
Why?
|
| Oligopeptides | 2 | 2020 | 132 | 0.420 |
Why?
|
| Allosteric Site | 3 | 2024 | 31 | 0.410 |
Why?
|
| Leucine | 2 | 2011 | 61 | 0.410 |
Why?
|
| H-2 Antigens | 2 | 2010 | 67 | 0.400 |
Why?
|
| Proteome | 4 | 2018 | 149 | 0.400 |
Why?
|
| Cells, Cultured | 9 | 2019 | 2152 | 0.390 |
Why?
|
| Major Histocompatibility Complex | 3 | 2017 | 88 | 0.390 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2019 | 181 | 0.380 |
Why?
|
| Vaccinia | 2 | 2013 | 32 | 0.380 |
Why?
|
| Mass Spectrometry | 5 | 2019 | 301 | 0.380 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2021 | 147 | 0.370 |
Why?
|
| Solutions | 3 | 2021 | 64 | 0.350 |
Why?
|
| Interleukin-2 | 2 | 2023 | 166 | 0.350 |
Why?
|
| Antibodies, Viral | 1 | 2013 | 325 | 0.350 |
Why?
|
| Signal Transduction | 6 | 2018 | 3033 | 0.340 |
Why?
|
| Lymph Nodes | 2 | 2024 | 224 | 0.340 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2007 | 73 | 0.340 |
Why?
|
| B-Lymphocytes | 3 | 2025 | 574 | 0.340 |
Why?
|
| Protein Array Analysis | 2 | 2010 | 26 | 0.320 |
Why?
|
| Glycoproteins | 3 | 2024 | 187 | 0.320 |
Why?
|
| Structure-Activity Relationship | 4 | 2019 | 371 | 0.310 |
Why?
|
| Jurkat Cells | 3 | 2018 | 110 | 0.300 |
Why?
|
| HIV Core Protein p24 | 2 | 2005 | 17 | 0.290 |
Why?
|
| Proteins | 2 | 2013 | 751 | 0.290 |
Why?
|
| Ligands | 8 | 2018 | 416 | 0.280 |
Why?
|
| Immunotherapy | 3 | 2025 | 255 | 0.280 |
Why?
|
| Cloning, Molecular | 4 | 2021 | 382 | 0.270 |
Why?
|
| Vaccines | 1 | 2009 | 96 | 0.270 |
Why?
|
| Unilamellar Liposomes | 1 | 2006 | 9 | 0.270 |
Why?
|
| Leukocytes | 1 | 2007 | 104 | 0.260 |
Why?
|
| Receptors, Immunologic | 2 | 2006 | 177 | 0.260 |
Why?
|
| Molecular Probes | 2 | 2008 | 31 | 0.260 |
Why?
|
| Cell Differentiation | 3 | 2019 | 1348 | 0.260 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 93 | 0.260 |
Why?
|
| Phospholipids | 1 | 2006 | 81 | 0.260 |
Why?
|
| Molecular Structure | 3 | 2019 | 384 | 0.250 |
Why?
|
| Protein Subunits | 1 | 2006 | 166 | 0.250 |
Why?
|
| Mice, Transgenic | 7 | 2023 | 1276 | 0.250 |
Why?
|
| Receptors, Antigen, B-Cell | 2 | 2022 | 60 | 0.250 |
Why?
|
| Interferon-gamma | 6 | 2019 | 566 | 0.250 |
Why?
|
| Cell Compartmentation | 1 | 2005 | 36 | 0.250 |
Why?
|
| Adaptive Immunity | 2 | 2019 | 101 | 0.240 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2005 | 84 | 0.240 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 198 | 0.240 |
Why?
|
| Protein Structure, Quaternary | 4 | 2012 | 100 | 0.240 |
Why?
|
| Viral Envelope Proteins | 2 | 2018 | 102 | 0.230 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 3 | 2014 | 113 | 0.230 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 1465 | 0.220 |
Why?
|
| Alanine | 2 | 2004 | 51 | 0.220 |
Why?
|
| Membrane Proteins | 3 | 2021 | 894 | 0.210 |
Why?
|
| Insulin-Secreting Cells | 1 | 2025 | 190 | 0.210 |
Why?
|
| Bacterial Proteins | 2 | 2021 | 766 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 3 | 2008 | 863 | 0.210 |
Why?
|
| Tyrosine | 1 | 2004 | 94 | 0.210 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 451 | 0.210 |
Why?
|
| Hemagglutinins | 1 | 2023 | 17 | 0.210 |
Why?
|
| Esterases | 1 | 2023 | 13 | 0.210 |
Why?
|
| HLA-DRB1 Chains | 3 | 2015 | 16 | 0.200 |
Why?
|
| Seasons | 1 | 2023 | 134 | 0.200 |
Why?
|
| Orthomyxoviridae | 1 | 2002 | 26 | 0.200 |
Why?
|
| Alleles | 2 | 2022 | 447 | 0.200 |
Why?
|
| Neurodegenerative Diseases | 1 | 2025 | 143 | 0.200 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2022 | 15 | 0.200 |
Why?
|
| Thioctic Acid | 1 | 2002 | 7 | 0.190 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2023 | 113 | 0.190 |
Why?
|
| Apolipoprotein A-I | 1 | 2002 | 23 | 0.190 |
Why?
|
| Models, Structural | 1 | 2022 | 25 | 0.190 |
Why?
|
| Mammals | 1 | 2024 | 217 | 0.190 |
Why?
|
| Oxidoreductases | 1 | 2002 | 64 | 0.190 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2024 | 337 | 0.190 |
Why?
|
| Dimerization | 3 | 2008 | 145 | 0.190 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2019 | 148 | 0.190 |
Why?
|
| Shigella | 1 | 2021 | 8 | 0.190 |
Why?
|
| Dysentery, Bacillary | 1 | 2021 | 14 | 0.190 |
Why?
|
| Chemotactic Factors | 1 | 2021 | 26 | 0.190 |
Why?
|
| Enzyme Inhibitors | 1 | 2024 | 373 | 0.190 |
Why?
|
| Protein Conformation, beta-Strand | 1 | 2021 | 10 | 0.180 |
Why?
|
| Protein Conformation, alpha-Helical | 1 | 2021 | 22 | 0.180 |
Why?
|
| Chromatography, Gel | 4 | 2011 | 65 | 0.180 |
Why?
|
| Antibody Affinity | 2 | 2014 | 19 | 0.180 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2002 | 248 | 0.180 |
Why?
|
| Hybridomas | 2 | 2019 | 63 | 0.170 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2021 | 94 | 0.170 |
Why?
|
| Gene Expression | 2 | 2021 | 839 | 0.170 |
Why?
|
| Integrins | 2 | 2014 | 108 | 0.170 |
Why?
|
| Molecular Biology | 1 | 2021 | 67 | 0.170 |
Why?
|
| HLA-B Antigens | 1 | 2020 | 13 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2025 | 621 | 0.160 |
Why?
|
| Narcolepsy | 1 | 2019 | 1 | 0.160 |
Why?
|
| Orexins | 1 | 2019 | 6 | 0.160 |
Why?
|
| Insulin | 1 | 2024 | 686 | 0.160 |
Why?
|
| Spleen | 1 | 2021 | 483 | 0.160 |
Why?
|
| Genes, T-Cell Receptor delta | 1 | 2019 | 2 | 0.160 |
Why?
|
| Persian Gulf Syndrome | 1 | 2019 | 2 | 0.160 |
Why?
|
| Genes, T-Cell Receptor gamma | 1 | 2019 | 3 | 0.160 |
Why?
|
| Immediate-Early Proteins | 1 | 2019 | 45 | 0.160 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2014 | 41 | 0.160 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 1649 | 0.160 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2019 | 8 | 0.160 |
Why?
|
| Antigens, CD | 2 | 2013 | 347 | 0.160 |
Why?
|
| HLA-DR3 Antigen | 1 | 2019 | 7 | 0.160 |
Why?
|
| Molecular Docking Simulation | 1 | 2019 | 79 | 0.160 |
Why?
|
| Natural Killer T-Cells | 1 | 2019 | 29 | 0.160 |
Why?
|
| Self Tolerance | 1 | 2019 | 20 | 0.160 |
Why?
|
| Permethrin | 1 | 2019 | 10 | 0.160 |
Why?
|
| Mutation | 4 | 2017 | 2607 | 0.150 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 49 | 0.150 |
Why?
|
| Epithelial Cells | 1 | 2021 | 389 | 0.150 |
Why?
|
| Stress, Physiological | 1 | 2021 | 193 | 0.150 |
Why?
|
| Cell Adhesion Molecules | 1 | 2019 | 90 | 0.150 |
Why?
|
| Drug Discovery | 1 | 2019 | 95 | 0.150 |
Why?
|
| Computational Biology | 1 | 2021 | 356 | 0.150 |
Why?
|
| Neutrophils | 1 | 2021 | 376 | 0.150 |
Why?
|
| Surface Plasmon Resonance | 2 | 2011 | 34 | 0.150 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 136 | 0.150 |
Why?
|
| Protein Folding | 2 | 2011 | 267 | 0.150 |
Why?
|
| Brain | 2 | 2025 | 1555 | 0.150 |
Why?
|
| Photochemical Processes | 1 | 2018 | 17 | 0.150 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2019 | 103 | 0.150 |
Why?
|
| HeLa Cells | 1 | 2019 | 535 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2022 | 692 | 0.140 |
Why?
|
| Vaccination | 2 | 2013 | 363 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 148 | 0.140 |
Why?
|
| Herpesvirus 4, Human | 1 | 2019 | 196 | 0.140 |
Why?
|
| Intestines | 2 | 2021 | 167 | 0.140 |
Why?
|
| Alzheimer Disease | 1 | 2025 | 721 | 0.140 |
Why?
|
| Trans-Activators | 1 | 2019 | 314 | 0.140 |
Why?
|
| Liver | 1 | 2022 | 851 | 0.140 |
Why?
|
| Escherichia coli | 3 | 2011 | 700 | 0.140 |
Why?
|
| Protein Stability | 2 | 2016 | 92 | 0.140 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2017 | 4 | 0.140 |
Why?
|
| Ultraviolet Rays | 1 | 2018 | 136 | 0.140 |
Why?
|
| Transfection | 1 | 2019 | 692 | 0.140 |
Why?
|
| Shigella flexneri | 1 | 2017 | 19 | 0.140 |
Why?
|
| Host-Pathogen Interactions | 2 | 2017 | 262 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 491 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2019 | 211 | 0.130 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2008 | 182 | 0.130 |
Why?
|
| ROC Curve | 1 | 2018 | 281 | 0.130 |
Why?
|
| DNA, Viral | 1 | 2018 | 232 | 0.130 |
Why?
|
| Protein Domains | 1 | 2017 | 147 | 0.130 |
Why?
|
| Fluorometry | 1 | 2016 | 5 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 388 | 0.120 |
Why?
|
| Melanoma | 1 | 2019 | 331 | 0.120 |
Why?
|
| Fluorescence Polarization Immunoassay | 1 | 2015 | 8 | 0.120 |
Why?
|
| Hot Temperature | 1 | 2016 | 130 | 0.120 |
Why?
|
| Bacteria | 1 | 2018 | 304 | 0.120 |
Why?
|
| Intestinal Mucosa | 1 | 2017 | 245 | 0.120 |
Why?
|
| Staining and Labeling | 2 | 2008 | 125 | 0.110 |
Why?
|
| Macrophages | 2 | 2019 | 1038 | 0.110 |
Why?
|
| HLA-DR alpha-Chains | 1 | 2014 | 4 | 0.110 |
Why?
|
| Rotavirus Infections | 1 | 2014 | 1 | 0.110 |
Why?
|
| Receptors, CCR | 1 | 2014 | 2 | 0.110 |
Why?
|
| Malaria Vaccines | 1 | 2014 | 37 | 0.110 |
Why?
|
| Rotavirus | 1 | 2014 | 10 | 0.110 |
Why?
|
| Structural Homology, Protein | 1 | 2013 | 20 | 0.110 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2014 | 93 | 0.110 |
Why?
|
| Thermodynamics | 3 | 2017 | 196 | 0.110 |
Why?
|
| Crystallization | 2 | 2004 | 99 | 0.110 |
Why?
|
| In Vitro Techniques | 3 | 2005 | 488 | 0.110 |
Why?
|
| Glycocalyx | 1 | 2013 | 3 | 0.110 |
Why?
|
| Protein Transport | 1 | 2015 | 401 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 663 | 0.110 |
Why?
|
| Receptors, Virus | 1 | 2014 | 73 | 0.110 |
Why?
|
| Flow Cytometry | 2 | 2008 | 661 | 0.110 |
Why?
|
| Clathrin-Coated Vesicles | 1 | 2013 | 8 | 0.110 |
Why?
|
| Drosophila | 2 | 2019 | 435 | 0.110 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2013 | 53 | 0.100 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2013 | 21 | 0.100 |
Why?
|
| Smallpox | 1 | 2013 | 9 | 0.100 |
Why?
|
| Protein Engineering | 1 | 2013 | 82 | 0.100 |
Why?
|
| Chromatography, Liquid | 2 | 2015 | 131 | 0.100 |
Why?
|
| Peptide Biosynthesis | 1 | 2012 | 10 | 0.100 |
Why?
|
| Genes, MHC Class I | 1 | 2012 | 27 | 0.100 |
Why?
|
| Substrate Specificity | 2 | 2011 | 335 | 0.100 |
Why?
|
| Half-Life | 1 | 2012 | 80 | 0.100 |
Why?
|
| Immunologic Surveillance | 1 | 2012 | 22 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 175 | 0.100 |
Why?
|
| Genes, MHC Class II | 2 | 2009 | 37 | 0.100 |
Why?
|
| Models, Biological | 2 | 2017 | 1177 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2013 | 319 | 0.100 |
Why?
|
| Molecular Chaperones | 1 | 2012 | 99 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2013 | 185 | 0.090 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2012 | 78 | 0.090 |
Why?
|
| Crystallography | 1 | 2011 | 26 | 0.090 |
Why?
|
| Mutagenesis | 1 | 2012 | 132 | 0.090 |
Why?
|
| Chromatography, Affinity | 1 | 2011 | 48 | 0.090 |
Why?
|
| Fluorescence | 1 | 2011 | 91 | 0.090 |
Why?
|
| Male | 8 | 2024 | 29814 | 0.090 |
Why?
|
| Microglia | 2 | 2005 | 242 | 0.090 |
Why?
|
| Drosophila melanogaster | 2 | 2012 | 498 | 0.090 |
Why?
|
| Interleukin-4 | 2 | 2007 | 141 | 0.080 |
Why?
|
| Cricetinae | 1 | 2010 | 366 | 0.080 |
Why?
|
| Protein Denaturation | 2 | 2016 | 67 | 0.080 |
Why?
|
| Circular Dichroism | 2 | 2016 | 108 | 0.080 |
Why?
|
| Female | 7 | 2024 | 32787 | 0.080 |
Why?
|
| Biotinylation | 2 | 2006 | 36 | 0.080 |
Why?
|
| Vaccines, Subunit | 1 | 2009 | 41 | 0.080 |
Why?
|
| Catalysis | 2 | 2012 | 161 | 0.080 |
Why?
|
| Phosphorylation | 2 | 2017 | 937 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2009 | 160 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1617 | 0.070 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2007 | 50 | 0.070 |
Why?
|
| Drug Design | 1 | 2009 | 135 | 0.070 |
Why?
|
| Antigens, Differentiation | 1 | 2007 | 138 | 0.070 |
Why?
|
| Mice, Knockout | 3 | 2014 | 2107 | 0.070 |
Why?
|
| Immunophenotyping | 1 | 2007 | 195 | 0.070 |
Why?
|
| Conserved Sequence | 2 | 2007 | 174 | 0.070 |
Why?
|
| Electrons | 1 | 2007 | 36 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2024 | 620 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2007 | 105 | 0.070 |
Why?
|
| CD3 Complex | 1 | 2006 | 65 | 0.070 |
Why?
|
| Cell Lineage | 1 | 2007 | 268 | 0.060 |
Why?
|
| Arginine | 1 | 2007 | 124 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2007 | 231 | 0.060 |
Why?
|
| Histocompatibility Antigen H-2D | 1 | 2006 | 6 | 0.060 |
Why?
|
| CD8 Antigens | 1 | 2006 | 54 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 860 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 2180 | 0.060 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2005 | 47 | 0.060 |
Why?
|
| CD13 Antigens | 1 | 2005 | 6 | 0.060 |
Why?
|
| Cytoplasmic Vesicles | 1 | 2005 | 7 | 0.060 |
Why?
|
| Clone Cells | 2 | 2002 | 114 | 0.060 |
Why?
|
| Solubility | 1 | 2006 | 179 | 0.060 |
Why?
|
| Neuropeptides | 1 | 2005 | 82 | 0.060 |
Why?
|
| Myeloid Cells | 1 | 2005 | 94 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 614 | 0.060 |
Why?
|
| Lysosomes | 1 | 2005 | 167 | 0.060 |
Why?
|
| Asthma | 1 | 2009 | 440 | 0.060 |
Why?
|
| Forkhead Transcription Factors | 2 | 2019 | 129 | 0.060 |
Why?
|
| Static Electricity | 2 | 2017 | 167 | 0.050 |
Why?
|
| Cystinyl Aminopeptidase | 1 | 2024 | 2 | 0.050 |
Why?
|
| Ultracentrifugation | 1 | 2004 | 28 | 0.050 |
Why?
|
| Intracellular Fluid | 1 | 2004 | 32 | 0.050 |
Why?
|
| Scattering, Radiation | 1 | 2004 | 73 | 0.050 |
Why?
|
| RNA Editing | 1 | 2004 | 23 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2004 | 102 | 0.050 |
Why?
|
| Sarcosine | 1 | 2003 | 2 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 240 | 0.050 |
Why?
|
| Allosteric Regulation | 1 | 2024 | 69 | 0.050 |
Why?
|
| Cricetulus | 1 | 2024 | 99 | 0.050 |
Why?
|
| Haplotypes | 2 | 2015 | 131 | 0.050 |
Why?
|
| CHO Cells | 1 | 2024 | 188 | 0.050 |
Why?
|
| Cross-Linking Reagents | 1 | 2004 | 116 | 0.050 |
Why?
|
| Methylation | 1 | 2003 | 129 | 0.050 |
Why?
|
| Tissue Donors | 2 | 2015 | 152 | 0.050 |
Why?
|
| Light | 1 | 2004 | 202 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2005 | 493 | 0.050 |
Why?
|
| Spodoptera | 1 | 2002 | 28 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2024 | 102 | 0.050 |
Why?
|
| Temperature | 1 | 2004 | 307 | 0.050 |
Why?
|
| Methionine Sulfoxide Reductases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Dimyristoylphosphatidylcholine | 1 | 2002 | 5 | 0.050 |
Why?
|
| HIV Infections | 2 | 2007 | 967 | 0.050 |
Why?
|
| Models, Immunological | 1 | 2002 | 85 | 0.050 |
Why?
|
| Indicators and Reagents | 1 | 2002 | 52 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2002 | 36 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2004 | 383 | 0.050 |
Why?
|
| Animals, Newborn | 1 | 2002 | 236 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 325 | 0.040 |
Why?
|
| Immunoglobulin Joining Region | 1 | 2019 | 1 | 0.040 |
Why?
|
| Peripheral Tolerance | 1 | 2019 | 3 | 0.040 |
Why?
|
| Base Sequence | 1 | 2002 | 1329 | 0.040 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2021 | 199 | 0.040 |
Why?
|
| HLA-DQ Antigens | 1 | 2019 | 14 | 0.040 |
Why?
|
| Gulf War | 1 | 2019 | 5 | 0.040 |
Why?
|
| Pyridostigmine Bromide | 1 | 2019 | 5 | 0.040 |
Why?
|
| Benzoates | 1 | 2019 | 8 | 0.040 |
Why?
|
| Cell Movement | 1 | 2021 | 452 | 0.040 |
Why?
|
| Protein Aggregation, Pathological | 1 | 2019 | 19 | 0.040 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2019 | 17 | 0.040 |
Why?
|
| Glycosylation | 1 | 2019 | 138 | 0.040 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2019 | 86 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2002 | 771 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 130 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 278 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 2018 | 28 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2019 | 186 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 206 | 0.040 |
Why?
|
| Tight Junctions | 1 | 2017 | 20 | 0.030 |
Why?
|
| Permeability | 1 | 2017 | 49 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2019 | 197 | 0.030 |
Why?
|
| Salts | 1 | 2017 | 15 | 0.030 |
Why?
|
| Lepidoptera | 1 | 2017 | 9 | 0.030 |
Why?
|
| Baculoviridae | 1 | 2017 | 25 | 0.030 |
Why?
|
| Biocatalysis | 1 | 2017 | 48 | 0.030 |
Why?
|
| Neutrophil Infiltration | 1 | 2017 | 59 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 619 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2002 | 1539 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 268 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1121 | 0.030 |
Why?
|
| Gelsolin | 1 | 2016 | 5 | 0.030 |
Why?
|
| Collagen Type II | 1 | 2016 | 12 | 0.030 |
Why?
|
| Thymosin | 1 | 2016 | 8 | 0.030 |
Why?
|
| Phenotype | 1 | 2019 | 1200 | 0.030 |
Why?
|
| Complement C3 | 1 | 2016 | 59 | 0.030 |
Why?
|
| Cell Separation | 1 | 2015 | 147 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2019 | 985 | 0.030 |
Why?
|
| Virus Activation | 1 | 2014 | 24 | 0.030 |
Why?
|
| Virus Latency | 1 | 2014 | 32 | 0.030 |
Why?
|
| Cathepsins | 2 | 2005 | 34 | 0.030 |
Why?
|
| Time Factors | 3 | 2007 | 3759 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 107 | 0.030 |
Why?
|
| Adult | 3 | 2019 | 16782 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 334 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2013 | 105 | 0.030 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2013 | 59 | 0.030 |
Why?
|
| Inteins | 1 | 2012 | 3 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2013 | 251 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 233 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2012 | 264 | 0.020 |
Why?
|
| Veterans | 1 | 2019 | 764 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2012 | 174 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 242 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 263 | 0.020 |
Why?
|
| Polysaccharides | 1 | 2012 | 144 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 457 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1001 | 0.020 |
Why?
|
| Metalloproteases | 1 | 2010 | 4 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2010 | 76 | 0.020 |
Why?
|
| Receptors, Interleukin-10 | 1 | 2009 | 3 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 228 | 0.020 |
Why?
|
| Desensitization, Immunologic | 1 | 2009 | 12 | 0.020 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2009 | 25 | 0.020 |
Why?
|
| Placebos | 1 | 2009 | 72 | 0.020 |
Why?
|
| Cats | 1 | 2009 | 87 | 0.020 |
Why?
|
| Allergens | 1 | 2009 | 53 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2009 | 98 | 0.020 |
Why?
|
| Influenza A virus | 1 | 2010 | 123 | 0.020 |
Why?
|
| Biomarkers | 2 | 2005 | 1396 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 172 | 0.020 |
Why?
|
| Poxviridae | 1 | 2007 | 5 | 0.020 |
Why?
|
| Genes, Viral | 1 | 2007 | 57 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 738 | 0.020 |
Why?
|
| Gene Products, tat | 1 | 2007 | 14 | 0.020 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2007 | 13 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2007 | 73 | 0.020 |
Why?
|
| Micelles | 1 | 2007 | 80 | 0.020 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2007 | 26 | 0.020 |
Why?
|
| Gene Products, gag | 1 | 2007 | 64 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 363 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 94 | 0.020 |
Why?
|
| Gold Sodium Thiomalate | 1 | 2006 | 1 | 0.020 |
Why?
|
| Sodium Hypochlorite | 1 | 2006 | 12 | 0.020 |
Why?
|
| trans-Golgi Network | 1 | 2005 | 8 | 0.020 |
Why?
|
| Lymphoid Tissue | 1 | 2005 | 55 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2006 | 132 | 0.020 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2005 | 24 | 0.020 |
Why?
|
| Cisplatin | 1 | 2006 | 139 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 734 | 0.010 |
Why?
|
| Cell Communication | 1 | 2005 | 130 | 0.010 |
Why?
|
| Glycine | 1 | 2004 | 49 | 0.010 |
Why?
|
| Proline | 1 | 2004 | 44 | 0.010 |
Why?
|
| Multiprotein Complexes | 1 | 2005 | 153 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2006 | 309 | 0.010 |
Why?
|
| Child | 1 | 2014 | 4522 | 0.010 |
Why?
|
| Lung | 1 | 2009 | 953 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 230 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 4683 | 0.010 |
Why?
|
| Monocytes | 1 | 2005 | 353 | 0.010 |
Why?
|
| Biosensing Techniques | 1 | 2004 | 119 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 6238 | 0.010 |
Why?
|
| Receptors, Cytokine | 1 | 2002 | 13 | 0.010 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2002 | 32 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2002 | 16 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2002 | 33 | 0.010 |
Why?
|
| CD58 Antigens | 1 | 2002 | 2 | 0.010 |
Why?
|
| CD2 Antigens | 1 | 2002 | 3 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2002 | 189 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 99 | 0.010 |
Why?
|
| Middle Aged | 1 | 2019 | 17549 | 0.010 |
Why?
|
| Chemokines | 1 | 2002 | 93 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2002 | 160 | 0.010 |
Why?
|
| Cell Polarity | 1 | 2002 | 109 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 297 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2002 | 264 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 201 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2002 | 429 | 0.010 |
Why?
|